Physician profile
David G Callanan
NPI 1558360339
$58,698.50
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $8,747 · 2021: $654 · 2022: $224.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $18,717.68 | 2019-2022 | |
| Allergan, INC. | $14,924.83 | 2019 | |
| Shire North American Group INC | $7,830.00 | 2019 | |
| Genentech, INC. | $5,844.08 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $5,390.00 | 2020 | |
| F. Hoffmann-La Roche Ag | $3,691.25 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,500.00 | 2020 | |
| Alimera Sciences, INC. | $335.18 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $132.14 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $119.37 | 2021 | |
| Novartis Pharmaceuticals Corporation | $104.32 | 2019 | |
| Alcon Vision LLC | $64.11 | 2021 | |
| Mallinckrodt Enterprises LLC | $29.57 | 2019 | |
| Genentech USA, INC. | $15.97 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Research and ownership
$6,912.68 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Callanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.